Oruka Therapeutics, Inc. Common Stock (ORKA) Stock Price

ORKAStock

$101.82+563.34%52W

Market Cap$6.74B

P/E—

PEG Ratio—

Div yield—

Beta-0.43

ORKA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)206.14%

Price vs S&P 500 (4W)10.18%

VGM Score47.56

Book Value / Share (Quarterly)$9.70

P/TBV (Annual)2.93x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.82

Price vs S&P 500 (YTD)225.95%

Net Profit Margin (TTM)-26.27%

EPS (TTM)$-2.39

10-Day Avg Trading Volume0.86M

EPS Excl Extra (TTM)$-2.39

EPS (Annual)$-2.31

ROI (Annual)-22.34%

Net Profit Margin (5Y Avg)-9513.58%

Cash / Share (Quarterly)$7.75

ROA (Last FY)-21.58%

EBITD / Share (TTM)$-2.72

ROE (5Y Avg)-24.07%

Operating Margin (TTM)-40.31%

Cash Flow / Share (Annual)$-1.81

P/B Ratio14.61x

P/B Ratio (Quarterly)4.99x

Net Income / Employee (Annual)$-1,550,500

EV / Revenue (TTM)150.69x

Net Interest Coverage (TTM)-69.05x

ROA (TTM)-25.00%

EPS Incl Extra (Annual)$-2.31

Current Ratio (Annual)22.37x

Quick Ratio (Quarterly)23.38x

3-Month Avg Trading Volume1.50M

52-Week Price Return563.34%

Revenue / Employee (TTM)$0

P/S Ratio (Annual)151.75x

Asset Turnover (Annual)0.39x

52-Week High$115.52

Operating Margin (5Y Avg)-9138.63%

EPS Excl Extra (Annual)$-2.31

CapEx CAGR (5Y)59.89%

26-Week Price Return217.38%

Quick Ratio (Annual)21.92x

13-Week Price Return74.51%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)23.76x

Enterprise Value$7.06B

Asset Turnover (TTM)0.33x

Book Value / Share Growth (5Y)14.63%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-26.25%

Cash / Share (Annual)$6.92

3-Month Return Std Dev70.28%

Net Income / Employee (TTM)$-1,709,600

ROE (Last FY)-22.34%

Net Interest Coverage (Annual)-29.41x

EPS Basic Excl Extra (Annual)$-2.31

Receivables Turnover (TTM)10.19x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.39

Receivables Turnover (Annual)10.19x

ROI (TTM)-25.99%

P/S Ratio (TTM)151.75x

Pretax Margin (5Y Avg)-9092.39%

Revenue / Share (Annual)$0.00

Price vs S&P 500 (52W)545.03%

Year-to-Date Return237.91%

5-Day Price Return-9.43%

EPS Normalized (Annual)$-2.31

ROA (5Y Avg)-23.01%

Net Profit Margin (Annual)-26.25%

Month-to-Date Return6.12%

EBITD / Share (Annual)$-2.67

Operating Margin (Annual)-40.31%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-24.07%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-2.39

P/TBV (Quarterly)2.00x

P/B Ratio (Annual)3.11x

Pretax Margin (TTM)-26.27%

Book Value / Share (Annual)$9.69

Price vs S&P 500 (13W)71.72%

Beta-0.43x

Revenue / Share (TTM)$0.00

ROE (TTM)-25.99%

52-Week Low$14.34

vGradeF

mGradeA

vgmGradeC

ORKA Earnings Surprise History

Q2 25-0.46est. -0.43

Q3 25-0.55est. -0.52

Q4 25-0.45est. -0.62

Q1 26-0.48est. -0.54

Q2 26-0.55est. -0.50

ORKA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.40

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$67.01

About Oruka Therapeutics, Inc. Common Stock

Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibodies for psoriasis and inflammatory diseases. Its lead programs—ORKA-001 and ORKA-002—target distinct inflammatory pathways (IL-23p19 and IL-17A/F) using high-affinity antibodies with extended half-lives to reduce dosing frequency. Both programs address psoriasis, with ORKA-002 also designed for psoriatic arthritis and related conditions.